Background Glioblastoma is associated with a poor prognosis in the elderly. Survival has
been shown to increase among patients 70 years of age or younger when temozolomide …

PURPOSE: Radiotherapy (RT) and chemotherapy may prolong survival in older patients
(age≥ 70 years) with glioblastoma multiforme (GBM), although the survival benefits remain …

Objectives The optimal treatment for elderly patients (age> 70 years) with glioblastoma
remains controversial. We conducted a prospective trial in 32 consecutive elderly patients …

Background Most patients with glioblastoma are older than 60 years, but treatment
guidelines are based on trials in patients aged only up to 70 years. We did a randomised …

Importance Despite improvements in survival with aggressive chemoradiation, outcomes for
patients diagnosed as having glioblastoma multiforme (GBM) remain poor. Survival is further …

Purpose To evaluate 2 specific radiation schedules, each combined with temozolomide
(TMZ), assessing their efficacy and safety in patients aged≥ 65 years with newly diagnosed …

BACKGROUND: The addition of temozolomide (TMZ) to radiotherapy (RT) improves survival
of patients with glioblastoma (GB) when compared to postoperative RT alone in patients up …

BACKGROUND Elderly patients (age> 65 years) with glioblastoma multiforme frequently are
excluded from clinical studies, and prospective trials for patients with this age group do not …

Glioblastoma is the most common primary malignant brain tumor diagnosed in the USA and
is associated with a poor prognosis. The outcomes in elderly patients (more than 65 years of …

BACKGROUND The optimal treatment for elderly patients (defined as patients 70 years of
age or older) with malignant gliomas (MG) remains controversial. Some physicians advocate …